Literature DB >> 10944125

High-time chemotherapy or high time for low dose.

B A Kamen, E Rubin, J Aisner, E Glatstein.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 10944125     DOI： 10.1200/JCO.2000.18.16.2935

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  18 in total

1.  Oral low-dose chemotherapy: successful treatment of an alveolar rhabdomyosarcoma during pregnancy.

Authors:  Meinolf Siepermann; Ewa Koscielniak; Tobias Dantonello; Dirk Klee; Joachim Boos; Barbara Krefeld; Arndt Borkhardt; Thomas Hoehn; Alexzander Asea; Rüdiger Wessalowski
Journal:  Pediatr Blood Cancer       Date:  2011-01-16       Impact factor: 3.167

2.  Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma.

Authors:  Sridharan Gururangan; Jeanne Krauser; Melody A Watral; Tim Driscoll; Nicole Larrier; David A Reardon; Jeremy N Rich; Jennifer A Quinn; James J Vredenburgh; Annick Desjardins; Roger E McLendon; Herbert Fuchs; Joanne Kurtzberg; Henry S Friedman
Journal:  Neuro Oncol       Date:  2008-08-28       Impact factor: 12.300

3.  Nanodiamond delivery circumvents tumor resistance to doxorubicin.

Authors:  Xiao-wei Ma; Yu-liang Zhao; Xing-jie Liang
Journal:  Acta Pharmacol Sin       Date:  2011-05-02       Impact factor: 6.150

4.  Dynamical properties of a minimally parameterized mathematical model for metronomic chemotherapy.

Authors:  Heinz Schättler; Urszula Ledzewicz; Behrooz Amini
Journal:  J Math Biol       Date:  2015-06-19       Impact factor: 2.259

Review 5.  Metronomics: towards personalized chemotherapy?

Authors:  Nicolas André; Manon Carré; Eddy Pasquier
Journal:  Nat Rev Clin Oncol       Date:  2014-06-10       Impact factor: 66.675

6.  Pilot phase II study of metronomic chemotherapy in combination with bevacizumab in patients with advanced non-squamous non-small cell lung cancer.

Authors:  Benjamin S Jones; Mary S Jerome; Deborah Miley; Bradford E Jackson; Mollie R DeShazo; Vishnu V B Reddy; Karan P Singh; Olivia C Brown; Francisco Robert
Journal:  Lung Cancer       Date:  2017-02-09       Impact factor: 5.705

Review 7.  Contribution of tumoral and host solute carriers to clinical drug response.

Authors:  Jason A Sprowl; Torben S Mikkelsen; Hugh Giovinazzo; Alex Sparreboom
Journal:  Drug Resist Updat       Date:  2012-03-28       Impact factor: 18.500

8.  Chemotherapeutic dosing implicated by pharmacodynamic modeling of in vitro cytotoxic data: a case study of paclitaxel.

Authors:  Hua He; Yanguang Cao
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-08-31       Impact factor: 2.745

9.  Center of cancer systems biology second annual workshop--tumor metronomics: timing and dose level dynamics.

Authors:  Philip Hahnfeldt; Lynn Hlatky; Giannoula Lakka Klement
Journal:  Cancer Res       Date:  2013-03-14       Impact factor: 12.701

10.  Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.

Authors:  Giancarlo Pruneri; Kathryn P Gray; Andrea Vingiani; Giuseppe Viale; Giuseppe Curigliano; Carmen Criscitiello; István Láng; Thomas Ruhstaller; Lorenzo Gianni; Aron Goldhirsch; Roswitha Kammler; Karen N Price; Giuseppe Cancello; Elisabetta Munzone; Richard D Gelber; Meredith M Regan; Marco Colleoni
Journal:  Breast Cancer Res Treat       Date:  2016-07-02       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.